Evidence map›Paper›PMID 33628338›Full record

ArticleDisease markers2021

Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7.

Toshiya Miyauchi, Masahiro Takahashi, Koji Mitsuzuka, Yuriko Saiki, Teppei Okubo, Paula M Vertino, Akiteru Goto, Yoichi Arai, Akira Horii, Shinichi Fukushige

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Toshiya MiyauchiDivision of Pathology, Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan.
Masahiro TakahashiDivision of Pathology, Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan.
Koji MitsuzukaDepartment of Urology, Tohoku University School of Medicine, Sendai, Miyagi 980-8574, Japan.
Yuriko SaikiDivision of Pathology, Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan.
Teppei OkuboDepartment of Urology, Tohoku University School of Medicine, Sendai, Miyagi 980-8574, Japan.
Paula M VertinoDepartments of Biomedical Genetics and Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Akiteru GotoDepartment of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita 010-0825, Japan.
Yoichi AraiDepartment of Urology, Tohoku University School of Medicine, Sendai, Miyagi 980-8574, Japan.
Akira HoriiDivision of Pathology, Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan.ORCID https://orcid.org/0000-0002-3967-3291
Shinichi FukushigeDivision of Pathology, Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan.ORCID https://orcid.org/0000-0003-0588-6376
Tohoku University · JPAkita University · JPUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic gene silencing by aberrant DNA methylation leads to loss of key cellular pathways in tumorigenesis. In order to analyze the effects of DNA methylation on prostate cancer, we established LNCaP-derived human prostate cancer cells that can pharmacologically induce global reactivation of hypermethylated genes by the methyl-CpG targeted transcriptional activation (MeTA) method. The MeTA suppressed the growth of LNCaP-derived cells and induced apoptosis. Microarray analysis indicated that

Indexed as

DNA MethylationEpigenesis, GeneticAgedApoptosis Regulatory ProteinsCarcinogenesisCARD Signaling Adaptor ProteinsCell LineCell Line, TumorCpG IslandsEpithelial CellsGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMitochondrial ProteinsNeoplasm GradingApoptosis Regulatory ProteinsBIK protein, humanCARD Signaling Adaptor ProteinsCIDEA protein, humanHRK protein, humanMitochondrial ProteinsPYCARD protein, humanReceptors, Tumor Necrosis Factor, Member 25TNFRSF25 protein, human

Identifiers

PMID33628338
PMCPMC7881737
OpenAlexW3129069870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.